Tectonic Therapeutic, Inc.
🇺🇸United States
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
Phase 2
Recruiting
- Conditions
- Pulmonary HypertensionHeart Failure With Preserved Ejection Fraction
- Interventions
- Drug: PlaceboDrug: TX000045- Dose ADrug: TX000045- Dose B
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Tectonic Therapeutic
- Target Recruit Count
- 180
- Registration Number
- NCT06616974
- Locations
- 🇪🇸
Valencia, Valencia, Spain
🇹🇷Gaziantep, Gaziantep, Turkey
🇹🇷Istanbul, Istanbul, Turkey
© Copyright 2025. All Rights Reserved by MedPath